KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Research & Development: 2009-2025

Historic Research & Development for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to $409.5 million.

  • Biomarin Pharmaceutical's Research & Development rose 121.46% to $409.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 15.78%. This contributed to the annual value of $747.2 million for FY2024, which is 0.06% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Research & Development stood at $409.5 million, which was up 153.85% from $161.3 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Research & Development ranged from a high of $409.5 million in Q3 2025 and a low of $148.7 million during Q1 2021.
  • For the 3-year period, Biomarin Pharmaceutical's Research & Development averaged around $202.1 million, with its median value being $183.8 million (2024).
  • The largest annual percentage gain for Biomarin Pharmaceutical's Research & Development in the last 5 years was 121.46% (2025), contrasted with its biggest fall of 22.57% (2025).
  • Over the past 5 years, Biomarin Pharmaceutical's Research & Development (Quarterly) stood at $161.1 million in 2021, then increased by 7.24% to $172.8 million in 2022, then rose by 19.39% to $206.2 million in 2023, then decreased by 15.87% to $173.5 million in 2024, then soared by 121.46% to $409.5 million in 2025.
  • Its Research & Development was $409.5 million in Q3 2025, compared to $161.3 million in Q2 2025 and $158.7 million in Q1 2025.